Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Science Translational Medicine|March 2, 2021
TCR β chain-directed bispecific antibodies for the treatment of T cell cancersSuman Paul, Alexander H Pearlman, Jacqueline Douglass, et al.Nature Communications|August 21, 2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigenKatharine M Wright, Sarah R DiNapoli, Michelle S Miller, et al.Nature Communications|September 7, 2021
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigensMichael S Hwang, Michelle S Miller, Puchong Thirawatananond, et al.Science Translational Medicine|July 10, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J Mog, Nikita Marcou, Sarah R DiNapoli, et al.Science (New York, N.Y.)|March 2, 2021
Targeting a neoantigen derived from a common TP53 mutationEmily Han-Chung Hsiue, Katharine M Wright, Jacqueline Douglass, et al.Nature|March 28, 2024
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancersTushar D Nichakawade, Jiaxin Ge, Brian J Mog, et al.Science Immunology|March 2, 2021
Bispecific antibodies targeting mutant RAS neoantigensJacqueline Douglass, Emily Han-Chung Hsiue, Brian J Mog, et al.The Journal of Clinical Investigation|January 16, 2026
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirementsSarah R DiNapoli, Katharine M Wright, Brian J Mog, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.Pageof 2